JW Lifescience Corporation (KRX:234080)
11,400
-100 (-0.87%)
At close: Mar 25, 2025, 3:30 PM KST
JW Lifescience Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2019 - 2015 |
---|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2019 - 2015 |
Operating Revenue | 222,478 | 206,860 | 188,931 | 169,817 | 183,521 | Upgrade
|
Other Revenue | - | - | -0 | -0 | - | Upgrade
|
Revenue | 222,478 | 206,860 | 188,931 | 169,817 | 183,521 | Upgrade
|
Revenue Growth (YoY) | 7.55% | 9.49% | 11.26% | -7.47% | 7.81% | Upgrade
|
Cost of Revenue | 165,010 | 154,507 | 140,972 | 120,788 | 124,243 | Upgrade
|
Gross Profit | 57,468 | 52,353 | 47,959 | 49,029 | 59,278 | Upgrade
|
Selling, General & Admin | 16,518 | 15,100 | 13,358 | 12,908 | 13,180 | Upgrade
|
Research & Development | 4,030 | 5,161 | 5,737 | 6,242 | 5,195 | Upgrade
|
Other Operating Expenses | 262.41 | 161.56 | 159.04 | 162.39 | 199.85 | Upgrade
|
Operating Expenses | 21,610 | 21,491 | 20,870 | 20,612 | 19,827 | Upgrade
|
Operating Income | 35,858 | 30,862 | 27,089 | 28,417 | 39,451 | Upgrade
|
Interest Expense | -2,061 | -2,693 | -3,092 | -1,281 | -2,609 | Upgrade
|
Interest & Investment Income | 1,506 | 1,130 | 1,087 | 130.36 | 1,427 | Upgrade
|
Earnings From Equity Investments | 10,392 | 6,489 | -4,921 | -4,780 | -7,129 | Upgrade
|
Currency Exchange Gain (Loss) | -2,570 | -651.41 | 329.73 | -149.04 | -150.86 | Upgrade
|
Other Non Operating Income (Expenses) | 15,864 | -1,251 | 296.71 | -3,772 | -8,197 | Upgrade
|
EBT Excluding Unusual Items | 58,989 | 33,886 | 20,789 | 18,565 | 22,791 | Upgrade
|
Gain (Loss) on Sale of Investments | 46.49 | - | - | - | - | Upgrade
|
Gain (Loss) on Sale of Assets | 4.9 | - | - | 1.71 | -4.14 | Upgrade
|
Asset Writedown | -14.09 | -166.58 | -7.42 | -279.65 | -46.75 | Upgrade
|
Other Unusual Items | - | -10.72 | - | - | - | Upgrade
|
Pretax Income | 59,027 | 33,708 | 20,782 | 18,287 | 22,740 | Upgrade
|
Income Tax Expense | 15,039 | 5,564 | 5,821 | 5,373 | 5,440 | Upgrade
|
Net Income | 43,988 | 28,144 | 14,961 | 12,914 | 17,300 | Upgrade
|
Net Income to Common | 43,988 | 28,144 | 14,961 | 12,914 | 17,300 | Upgrade
|
Net Income Growth | 56.29% | 88.11% | 15.86% | -25.36% | -21.14% | Upgrade
|
Shares Outstanding (Basic) | 15 | 15 | 15 | 16 | 16 | Upgrade
|
Shares Outstanding (Diluted) | 15 | 15 | 15 | 16 | 16 | Upgrade
|
Shares Change (YoY) | 0.01% | -0.03% | -0.61% | -1.61% | - | Upgrade
|
EPS (Basic) | 2841.00 | 1818.00 | 966.21 | 828.84 | 1092.55 | Upgrade
|
EPS (Diluted) | 2841.00 | 1818.00 | 966.00 | 828.84 | 1092.55 | Upgrade
|
EPS Growth | 56.27% | 88.20% | 16.55% | -24.14% | -21.14% | Upgrade
|
Free Cash Flow | 40,383 | 29,421 | 6,049 | 11,189 | 30,824 | Upgrade
|
Free Cash Flow Per Share | 2608.20 | 1900.50 | 390.67 | 718.13 | 1946.62 | Upgrade
|
Dividend Per Share | - | - | 500.000 | 500.000 | 500.000 | Upgrade
|
Gross Margin | 25.83% | 25.31% | 25.38% | 28.87% | 32.30% | Upgrade
|
Operating Margin | 16.12% | 14.92% | 14.34% | 16.73% | 21.50% | Upgrade
|
Profit Margin | 19.77% | 13.61% | 7.92% | 7.60% | 9.43% | Upgrade
|
Free Cash Flow Margin | 18.15% | 14.22% | 3.20% | 6.59% | 16.80% | Upgrade
|
EBITDA | 51,595 | 46,393 | 42,045 | 41,661 | 51,697 | Upgrade
|
EBITDA Margin | 23.19% | 22.43% | 22.25% | 24.53% | 28.17% | Upgrade
|
D&A For EBITDA | 15,737 | 15,531 | 14,956 | 13,245 | 12,246 | Upgrade
|
EBIT | 35,858 | 30,862 | 27,089 | 28,417 | 39,451 | Upgrade
|
EBIT Margin | 16.12% | 14.92% | 14.34% | 16.73% | 21.50% | Upgrade
|
Effective Tax Rate | 25.48% | 16.51% | 28.01% | 29.38% | 23.92% | Upgrade
|
Advertising Expenses | 1,564 | 1,731 | 1,605 | 1,666 | 1,039 | Upgrade
|
Updated Mar 18, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.